ArticleClinical case reports2024

Secukinumab (Anti-IL-17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS.

Mihkel Plaas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.